01 Increasing Use of Advanced Bioanalytical Assays for Biologics Development The large molecule bioanalytical testing services market is shifting toward more sophisticated ligand-binding, chromatographic, and biomarker assays capable of characterizing therapeutic proteins and other biologics across development stages. As biologic molecules become more complex, sponsors require validated methods that can reliably quantify drug concentrations and assess pharmacokinetic, pharmacodynamic, and biomarker responses in biological matrices. This is increasing demand for specialized laboratories with expertise in assay development, validation, and regulated sample analysis. In April 2026, the FDA issued final guidance on bioanalytical method validation for biomarkers, extending regulatory recommendations for validated methods used to measure biomarker concentrations in clinical and nonclinical samples.
02 Growing Focus on Immunogenicity and Biosimilar Analytical Testing The market is increasingly incorporating immunogenicity testing and comparative analytical assessment into large-molecule development programs. Therapeutic proteins can trigger anti-drug antibodies that influence pharmacokinetics, pharmacodynamics, safety, or efficacy, making reliable immunogenicity assessment important during clinical development. At the same time, biosimilar development requires extensive analytical characterization of the proposed product against its reference biologic, expanding demand for specialized bioanalytical capabilities. In September 2025, the FDA finalized guidance on comparative analytical assessment for therapeutic protein biosimilars, reinforcing the role of analytical studies in demonstrating biosimilarity and supporting regulatory submissions.
01 Expansion of Biologic Drug Development Supports Demand for Specialized Testing Increasing development of therapeutic proteins and other biological medicines creates a direct need for quantitative bioanalytical testing throughout nonclinical and clinical development. Large molecules require specialized assays because their size, structure, biological activity, and interactions with endogenous components can complicate measurement compared with conventional small molecules. Sponsors therefore increasingly rely on laboratories with validated ligand-binding, chromatographic, immunogenicity, and biomarker-testing capabilities.
01 High Assay Development and Validation Requirements Increase Testing Costs Large-molecule bioanalytical assays require extensive development and validation to demonstrate specificity, selectivity, accuracy, precision, sensitivity, and reliability in complex biological matrices. Ligand-binding assays can also require product-specific optimization because interactions with endogenous proteins, soluble targets, and other matrix components can affect measurement. These requirements increase laboratory resources, validation timelines, and overall testing costs.
01 Growth of Biosimilars Creates Opportunities for Comparative Bioanalytical Services Expansion of biosimilar development is creating additional demand for laboratories capable of performing highly sensitive comparative analytical assessments. Sponsors must establish that proposed therapeutic proteins are highly similar to reference products, requiring detailed analytical characterization and supporting bioanalytical studies. Contract testing organizations with validated platforms and regulatory expertise can capture outsourcing demand from developers seeking to accelerate biosimilar programs.
01 Assay Variability and Immunogenicity Assessment Complexity Challenge Testing Reliability Large-molecule assays can be affected by analyte structure, endogenous targets, matrix effects, sample handling, assay reagents, and differences in assay sensitivity and specificity. Contract laboratories must therefore maintain robust validation, standardized procedures, and appropriate controls to produce data that remain scientifically reliable and acceptable for regulatory use.
June 2026 Charles River Laboratories expanded its large molecule bioanalytical testing services by introducing advanced ligand-binding assays, biomarker analysis, immunogenicity testing, and pharmacokinetic evaluation capabilities. The expansion supports pharmaceutical and biotechnology companies in accelerating biologics development while ensuring regulatory compliance and high-quality analytical data.
April 2026 Labcorp Drug Development expanded its bioanalytical services portfolio with enhanced testing solutions for monoclonal antibodies, biosimilars, antibody-drug conjugates, and other biologics. The upgraded platform offers improved assay sensitivity, automated workflows, and comprehensive regulatory support throughout clinical development.
January 2026 Eurofins Scientific expanded its biologics testing capabilities by launching advanced large molecule bioanalytical services featuring biomarker testing, cell-based assays, immunogenicity assessments, and pharmacokinetic analysis for global biopharmaceutical clients.
October 2025 SGS expanded its bioanalytical laboratory network by introducing advanced analytical platforms supporting large molecule characterization, method validation, and regulatory-compliant testing for biologic drug development.